EverFlex Post Approval Study

NACompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

January 14, 2013

Primary Completion Date

October 23, 2018

Study Completion Date

February 4, 2019

Conditions
Peripheral Arterial DiseaseLower Extremity Arterial Disease
Interventions
DEVICE

EverFlex™ Self-Expanding Peripheral Stent System

Using the EverFlex™ Self-Expanding Peripheral Stent System to treat atherosclerotic superficial femoral artery (SFA) and proximal popliteal lesions 4-18 cm long in subjects with Rutherford Clinical Categories 2-4.

Trial Locations (23)

15212

Allegheny General Hospital, Pittsburgh

19010

Lankenau Institute for Medical Research, Bryn Mawr

19147

Thomas Jefferson University, Philadelphia

19713

Christiana Care Health Services, Newark

27607

Wake Heart Research, Raleigh

30901

Augusta Vascular Center, Augusta

32216

First Coast Cardiovascular Institute, P.A., Jacksonville

37909

Premier Surgical Associates, Knoxville

48912

Sparrow Hospital, Lansing

50266

Central Iowa Hospital Corporation, Des Moines

54301

Bellin Memorial Hospital, Green Bay

55433

Mercy Hospital/Metropolitan Cardiology Consultants, Coon Rapids

57117

Sanford Research, Sioux Falls

57701

Black Hills Cardiovascular Research, Rapid City

60515

DuPage Medical Group, Downers Grove

61107

Rockford Cardiovascular Associates, Rockford

71103

Cardiovascular Solutions, LLC, Shreveport

74104

Oklahoma Heart Institute, Tulsa

78229

The University of Texas Health Science Center at San Antonio, San Antonio

85006

St. Luke's Medical Center, Phoenix

95355

Memorial Medical Center, Modesto

95819

Sutter Memorial Hospital, Sacramento

08015

Deborah Heart and Lung Center, Browns Mills

Sponsors
All Listed Sponsors
lead

Medtronic Endovascular

INDUSTRY

NCT01680835 - EverFlex Post Approval Study | Biotech Hunter | Biotech Hunter